Taibia Rahman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Taibia Rahman has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Bachana Aptsiauri
Tbilisi State Medical University, Georgia
1 shared publication - Emaan Rana
Department of Science University of Western Ontario London Ontario Canada
1 shared publication Fathima Ridha
David Tvildiani Medical University, Tbilisi, Georgia
1 shared publication- Heshwin Singh
Departments of Neurosurgery, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York
1 shared publication - Kunal Bhatt
David Tvildiani Medical University, Tbilisi, Georgia
1 shared publication - Magda Wojtara
Department of Research and Education, Oli Health Magazine Organization, Research, and Education, Kigali, Rwanda
1 shared publication
Latest Publications
- Open Access
- 9 June 2025
- Published by SAGE Publications in Sage Open Aging
- Vol. 11
A Pathway to Healthier Aging or an Illusion? A Narrative Review on Deprescribing Protocols for the Elderly
Polypharmacy is the concurrent use of many drugs increasingly prevalent in elderly populations worldwide, with over 50% of older adults taking more than five drugs. The rise in chronic conditions such as diabetes, hypertension, and dementia largely drives this trend. However, polypharmacy poses significant risks, including adverse drug events, falls, cognitive decline, and hospitalizations, particularly due to age-related physiological changes that alter drug metabolism and clearance. Vulnerable populations, especially those with comorbidities, face heightened risks of complications associated with polypharmacy, underscoring the need for effective management strategies. Despite extensive literature on polypharmacy, gaps remain in practical, evidence-based approaches to safely reduce medication burdens. Structured deprescribing protocols are emerging as a critical intervention for reducing inappropriate medication use, improving patient outcomes, and lowering healthcare costs. These protocols involve stepwise algorithms and tools for screening to find potentially inappropriate medications and clinical decision-making frameworks to prioritize deprescribing as it can reduce fall risk, hospitalizations, and healthcare costs while enhancing quality of life. This narrative review examines evidence from trials, cohort studies, and meta-analyses on deprescribing protocols, highlighting challenges like patient resistance and withdrawal effects. It emphasizes tailored approaches, patient engagement, and shared decision-making for safe, effective, patient-centered deprescribing across healthcare settings.
- 9 June 2025
- Published by SAGE Publications in Sage Open Aging
- Vol. 11
Open AccessA Pathway to Healthier Aging or an Illusion? A Narrative Review on Deprescribing Protocols for the Elderly
Polypharmacy is the concurrent use of many drugs increasingly prevalent in elderly populations worldwide, with over 50% of older adults taking more than five drugs. The rise in chronic conditions such as diabetes, hypertension, and dementia largely drives this trend. However, polypharmacy poses significant risks, including adverse drug events, falls, cognitive decline, and hospitalizations, particularly due to age-related physiological changes that alter drug metabolism and clearance. Vulnerable populations, especially those with comorbidities, face heightened risks of complications associated with polypharmacy, underscoring the need for effective management strategies. Despite extensive literature on polypharmacy, gaps remain in practical, evidence-based approaches to safely reduce medication burdens. Structured deprescribing protocols are emerging as a critical intervention for reducing inappropriate medication use, improving patient outcomes, and lowering healthcare costs. These protocols involve stepwise algorithms and tools for screening to find potentially inappropriate medications and clinical decision-making frameworks to prioritize deprescribing as it can reduce fall risk, hospitalizations, and healthcare costs while enhancing quality of life. This narrative review examines evidence from trials, cohort studies, and meta-analyses on deprescribing protocols, highlighting challenges like patient resistance and withdrawal effects. It emphasizes tailored approaches, patient engagement, and shared decision-making for safe, effective, patient-centered deprescribing across healthcare settings.
- Top Cited PapersOpen Access
- 30 August 2023
- Published by Wiley in Clinical and Translational Science
- Vol. 16 (11) , 2106-2111
Artificial intelligence in rare disease diagnosis and treatment
Artificial intelligence (AI) utilization in health care has grown over the past few years. It also has demonstrated potential in improving the efficiency of diagnosis and treatment. Some types of AI, such as machine learning, allow for the efficient analysis of vast datasets, identifying patterns, and generating key insights. Predictions can then be made for medical diagnosis and personalized treatment recommendations. The use of AI can bypass some conventional limitations associated with rare diseases. Namely, it can optimize traditional randomized control trials, and may eventually reduce costs for drug research and development. Recent advancements have enabled researchers to train models based on large datasets and then fine‐tune these models on smaller datasets typically associated with rare diseases. In this mini‐review, we discuss recent advancements in AI and how AI can be applied to streamline rare disease diagnosis and optimize treatment.
- 30 August 2023
- Published by Wiley in Clinical and Translational Science
- Vol. 16 (11) , 2106-2111
Top Cited PapersOpen AccessArtificial intelligence in rare disease diagnosis and treatment
Artificial intelligence (AI) utilization in health care has grown over the past few years. It also has demonstrated potential in improving the efficiency of diagnosis and treatment. Some types of AI, such as machine learning, allow for the efficient analysis of vast datasets, identifying patterns, and generating key insights. Predictions can then be made for medical diagnosis and personalized treatment recommendations. The use of AI can bypass some conventional limitations associated with rare diseases. Namely, it can optimize traditional randomized control trials, and may eventually reduce costs for drug research and development. Recent advancements have enabled researchers to train models based on large datasets and then fine‐tune these models on smaller datasets typically associated with rare diseases. In this mini‐review, we discuss recent advancements in AI and how AI can be applied to streamline rare disease diagnosis and optimize treatment.